SuperworthPluri PLUR
- Market cap
- $12.2M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 12.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1M
- −24% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −165.5%
Pluri trades at 12.0× sales. Revenue was $1M over the last twelve months, down 24% on a year earlier.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $54K−38% | $105K+5150% | $71K−18% | $96K−14% | $326K+504% | $185K+76% | $427K+501% | $398K+315% | $316K−3% | $198K+7% | $167K−61% | $335K−16% | |
| Cost of revenue | n/a | n/a | n/a | n/a | $126K | $74K | $291K | $191K | $201K+60% | $112K+51% | $111K−62% | $139K−27% |
| Gross profit | $54K | $105K | $71K | $92K | $200K+270% | $111K+6% | $136K+92% | $207K+125% | $115K−43% | $86K−23% | $56K−59% | $196K−5% |
| R&D | $3M−34% | $3M−22% | $3.1M−26% | $3.4M−4% | $2.9M−4% | $2.9M−1% | $3M−2% | $4M+18% | $3.9M+36% | $3.8M+31% | $4M+30% | $3.4M−16% |
| SG&A | $2.4M−11% | $2.4M−19% | $2.5M−17% | $2.7M−13% | $2.5M+3% | $2.1M−9% | $2.5M−1% | $2.8M+4% | $2.5M+1% | $2.8M+29% | $2.6M+6% | $2.4M−16% |
| −$5.4M−22% | −$5.2M−22% | −$5.5M−22% | −$6M−8% | −$5.2M−3% | −$5M−5% | −$5.4M−2% | −$6.6M+10% | −$6.3M+22% | −$6.5M+31% | −$6.5M+21% | −$5.5M−16% | |
| Interest expense | $214K+10% | $216K+2% | $218K+1% | $218K−1% | $217K+1% | $211K−2% | $212K−3% | $233K+7% | $229K+6% | $231K+10% | $237K+12% | $235K+1% |
| Pre-tax income | n/a | n/a | n/a | n/a | −$6M | −$3.1M | −$6.3M | −$7.8M | −$6.1M+2% | −$6.9M+121% | −$6.2M−2% | −$6.2M−20% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | −$8K | −$8K | −$8K | −$1K | |
| Net income | −$5M−19% | −$4.9M−40% | −$5.3M−31% | −$5.7M−11% | −$5.9M+19% | −$3M−40% | −$6.1M+16% | −$7.6M+33% | −$5.8M−1% | −$6.5M+121% | −$5.5M−10% | −$5.9M−23% |
| −$0.96−37% | −$0.96−50% | −$1.01−34% | −$1.06 | −$1.08+13% | −$0.53−45% | −$0.94−7% | $61.60 | −$0.65−40% | −$0.71+34% | −$0.55−42% | $38.56−37% | |
| 5.2M+27% | 5.2M+25% | 5.2M+5% | 5.4M+5% | 5.5M+6% | 5.6M+7% | 6.6M+26% | 7.8M+45% | 9M+65% | 9.3M+67% | 10.1M+53% | 10.7M+37% |
EPS, diluted: 21 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY11 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 274, the two on one basis (x10). 4 periods, Q4 FY21 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Pluri's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PLURPluri | $12.2M | n/m | n/a | 12.0× | −24% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $64.6M | 13.6× | 14.8× | 1.1× | +6% | 4.9% |
More on Pluri
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .